Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M704Revenue (TTM) $M95.7Net Margin (%)-158.5Altman Z-Score-6.4
Enterprise Value $M831EPS (TTM) $-1.3Operating Margin %-135.5Piotroski F-Score3
P/E(ttm)--Beneish M-Score-0.8Pre-tax Margin (%)-158.9Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio1.6Cash flow > EarningsY
Price/Sales6.55-y EBITDA Growth Rate %-31.8Current Ratio1.7Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-99.5Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M128ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with MACK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MACKJoel Greenblatt 2015-06-30 Sold Out $10.76 - $13.67
($12.09)
$ 5.50-55%Sold Out0
MACKJoel Greenblatt 2015-03-31 Buy $8.78 - $12.48
($10.82)
$ 5.50-49%New holding13,433
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MACK is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


MACK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
PORTER MICHAEL EDirector 2016-03-17Buy5,000$7.2-23.61view
PORTER MICHAEL EDirector 2016-03-15Buy5,000$7.65-28.1view
PORTER MICHAEL EDirector 2016-03-08Buy10,000$7.09-22.43view
PORTER MICHAEL EDirector 2016-03-03Buy15,000$6.39-13.93view
PORTER MICHAEL EDirector 2016-03-01Buy20,000$6.11-9.98view
Lee Vivian SDirector 2016-02-29Buy35,000$5.50view
McClements William M.Head of Corporate Operations 2016-02-29Buy2,000$5.72-3.85view
Stewart Edward J.Head of Commercial 2016-01-05Sell4,000$8-31.25view
Stewart Edward J.Head of Commercial 2015-12-01Sell5,000$9.33-41.05view
Stewart Edward J.Head of Commercial 2015-11-02Sell6,000$9.42-41.61view

Quarterly/Annual Reports about MACK:

    News about MACK:

    Articles On GuruFocus.com
    Weekly CEO Sells Highlight: Starbucks Corp, KD Supply Holdings Inc, Capital One Financial Corp, Merr Dec 14 2014 

    More From Other Websites
    Merrimack Announces Timing of Second Quarter 2016 Investor Conference Call Jul 19 2016
    Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold Jul 13 2016
    Merrimack Stock Up on Fast Track Status for Seribantumab Jul 07 2016
    FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer Jul 06 2016
    FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer Jul 06 2016
    Buy 5 Attractive Biotechs at Bargain Prices Jul 05 2016
    NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall... Jun 30 2016
    NAPOLI-1 Data Demonstrates ONIVYDE® Regimen Maintains Quality of Life While Improving Overall... Jun 30 2016
    The Quest for an Effective Treatment for Pancreatic Cancer Jun 22 2016
    Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in... Jun 21 2016
    Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on... Jun 21 2016
    Merrimack to Present New Analyses of Phase 3 NAPOLI-1 Data at the ESMO 18th World Congress on... Jun 21 2016
    MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 16 2016
    Merrimack Announces Positive Data on Oncology Candidate Jun 07 2016
    Final Analysis of First-in-Human Phase 1 Study of MM-151 Shows Positive Clinical Activity in... Jun 06 2016
    These 7 Stocks Under $10 Are About to Break Out Jun 03 2016
    Coverage initiated on Merrimack Pharma by Robert W. Baird May 27 2016
    Merrimack/Baxalta Start Study on Colorectal Cancer Drug May 20 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)